Principal Investigator
Alejandra Perez
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20250343
Clinical Trial Summary
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of RecurrenceA Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)
Phase
Phase III
Funding Agency/Sponsor
Industrial
Disease
Breast Cancer
Contact Information
Phone Number
305-243-2647